Login / Signup

ω-3 polyunsaturated fatty acid supplementation improves postabsorptive and prandial protein metabolism in patients with chronic obstructive pulmonary disease: a randomized clinical trial.

Marielle P K J EngelenRenate JonkerHooriya SulaimanHelena L FiskPhilip C CalderNicolaas E P Deutz
Published in: The American journal of clinical nutrition (2022)
Daily n-3 PUFA supplementation for 4 wk induces a shift toward a positive daily protein homeostasis in patients with COPD in part in a dose-dependent way. Daily doses up to 3.5 g EPA and DHA are still well tolerated and lead to protein gain in these patients. This trial was registered at clinicaltrials.gov as NCT01624792.
Keyphrases
  • fatty acid
  • end stage renal disease
  • physical activity
  • chronic kidney disease
  • ejection fraction
  • amino acid
  • clinical trial
  • chronic obstructive pulmonary disease
  • binding protein
  • randomized controlled trial